Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | TACR3 | P29371 | 10/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975021 | 0.92 | CYP2C9 (0.43) | CYP2C9TACR3OPRL1MEN1ALDH1A1 | |
| SCHEMBL1974913 | 0.92 | CYP2C9 (0.46) | CYP2C9TACR3OPRL1MEN1ALDH1A1 | |
| SCHEMBL1972416 | 0.88 | CYP2C9 (0.49) | CYP2C9TACR3MAPTSMYD3PPARG | |
| SCHEMBL1973603 | 0.88 | CYP2C9 (0.49) | CYP2C9TACR3MAPTSMYD3PPARG | |
| SCHEMBL10150597 | 0.85 | CYP2C9 (0.44) | CYP2C9TACR3OPRL1MEN1ALDH1A1 | |
| SCHEMBL1975909 | 0.84 | CYP2C9 (0.46) | CYP2C9TACR3OPRL1MEN1ALDH1A1 | |
| SCHEMBL11917800 | 0.83 | CYP2C9 (0.47) | CYP2C9TACR3OPRL1MEN1ALDH1A1 | |
| SCHEMBL1978893 | 0.83 | CYP2C9 (0.45) | CYP2C9TACR3OPRL1MEN1ALDH1A1 | |
| SCHEMBL1974466 | 0.83 | CYP2C9 (0.35) | CYP2C9TACR3SMYD3 | |
| SCHEMBL1974336 | 0.82 | CYP2C9 (0.45) | CYP2C9TACR3OPRL1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011072691-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | claimed |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2011-06-16 | — | — | US | claimed |
| US-8207347-B2 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-06-26 | — | — | US | disclosed |
| WO-2011072691-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011072691-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | KCNK3, GRIK3, KCND3 | CYP2C9 2501/4885TACR3 26/4885OPRL1 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.